# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k072246   
B. Purpose for Submission: New device   
C. Measurand: Quality controls for IgA, IgG, IgM; C3, C4, α1-Antitrypsin and Transferin   
D. Type of Test: Quantitative determination in automated, semi-automated, manual chemistry systems   
E. Applicant: Maine Standards Company   
F. Proprietary and Established Names: VALIDATE $^ \mathrm { \textregistered }$ SP1 Calibration Verification Test Set

# G. Regulatory Information:

1. Regulation section: 21 CFR $\ S$ 862.1660, Quality Control Material (Assayed and Unassayed)   
2. Classification: Class I   
3. Product codes: JJY, Multi-analyte controls, All kinds (Assayed and Unassayed)   
4. Panel: Chemistry (75)

# H. Intended Use:

1. Intended use(s): VALIDATE $^ \mathrm { \textregistered }$ SP1 Calibration Verification Test Set solutions are intended for in vitro diagnostic use in the quantitative determination of linearity, calibration verification and verification of reportable range in automated, semi-automated and manual chemistry systems for the following analytes: Immunoglobulin A (IgA), Immunoglobulin G, IgG), Immunoglobulin M (IgM), Complement C3 (C3), Complement C4 (C4), α1-Antitrypsin (AAT), and Transferrin (TRF).   
2. Indication(s) for use: Same as Intended use.   
3. Special conditions for use statement(s): For prescription only.   
4. Special instrument requirements: None

# I. Device Description:

VALIDATE $^ \mathrm { \textregistered }$ SP1 Calibration Verification Test Sets are human serum materials containing 5 levels of each of the seven analytes. Each test set consists of one bottle $( 1 . 0 \mathrm { m L } )$ each of Level 1 to Level 5.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Cliniqa LiniCAL $^ \mathrm { \textregistered }$ Calibration Verifier Protein 1

# Cliniqa LiniCAL $^ \mathrm { \textregistered }$ Calibration Verifier Protein 2

2. Predicate K number(s): k031575 (IgA, IgG, IgM, C3, C4, TRF) k031577 (AAT)

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>VALIDATE® SP1Calibration VerificationTest Set</td><td rowspan=1 colspan=1>Cliniqa LiniCAL®Calibration VerifierProtein 1 and Protein 2</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For in vitro diagnostic usein the quantitativedetermination of linearity,calibration verificationand verification ofreportable range inautomated, semi-automated and manualchemistry systems</td><td rowspan=1 colspan=1>For in vitro diagnosticuse in the clinicallaboratory to verifycalibration and/ or assesslinearity. Five assayedlevels are provided toallow monitoring of thereportable range</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Number of Levels</td><td rowspan=1 colspan=1>5 Levels</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Packaging</td><td rowspan=1 colspan=1>1.0 mL each level</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Liquid</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=4>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=2>Predicate Devices</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>VALIDATE® SP1Calibration VerificationTest Set</td><td rowspan=1 colspan=1>CliniqaLiniCALCalibrationVerifierProtein 1</td><td rowspan=1 colspan=1>CliniqaLiniCAL®CalibrationVerifierProtein 2</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>IgA, IgG, IgM, C3, C4,AAT, and TRF</td><td rowspan=1 colspan=1>IgA, IgG,IgM, C3, C4,and TRF</td><td rowspan=1 colspan=1>AAT, AAG,AMG, AT3,B2M, CER</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>One year</td><td rowspan=1 colspan=1>Opened vial:14 days</td><td rowspan=1 colspan=1>Opened vial:14 days</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>-10°C to -20°</td><td rowspan=1 colspan=1>2 - 8°</td><td rowspan=1 colspan=1>2 - 8°</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP6: Evaluation of linearity

L. Test Principle: Not applicable

M. Performance Characteristics (if/when applicable): 1. Analytical performance:

a. Precision/Reproducibility: Not applicable.   
$b$ . Linearity/assay reportable range: Not applicable.   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): Stability studies were performed with the acceptance criteria of $5 9 0 \%$ recovery from date of manufacture. Stability data showed shelf life of 2.5 years for $- 1 0 \mathrm { { ^ \circ C } }$ and 5 years for $- 2 0 \mathrm { { ^ \circ C } }$ . The expiration date claim is one year for -10 to $- 2 0 \mathrm { { ^ \circ C } }$ .   
d. Detection limit: Not applicable.   
$e$ . Analytical specificity: Not applicable.   
$f .$ Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device: Not applicable.   
b. Matrix comparison: Not applicable,

3. Clinical studies: a. Clinical Sensitivity: Not applicable. b. Clinical specificity: Not applicable. c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.   
5. Expected values/Reference range: Not applicable.

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.